Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCT／Sanofi-aventis: Clexane Kit for SC Injection
May 19, 2008
- TOPICS／Mylan Accepted as JPMA Member
May 19, 2008
- Asahi Kasei Pharma: Sales Up 6.5% to \111.2 Bil.
May 19, 2008
- Nihon Chouzai Promotes Dispensing of Generics
May 19, 2008
- Bonalon Drives Teijin's Pharma Business
May 19, 2008
- OBITUARY／Dr Yutaka Mizushima: Former Chairman of LTT-Bio Pharma
May 19, 2008
- Kyowa Hakko: Sales Up 10.7% to \392 Bil.
May 19, 2008
- REGULATORY NEWS IN BRIEF
May 19, 2008
- Santen: Overseas Sales Account for 14.3% of Total Sales
May 19, 2008
- Prof. H. Endo Elected Chairman of Chuikyo
May 19, 2008
- MTPC: Remicade Continues Strong Growth
May 19, 2008
- JMA Has Not Yet Decided on Its Stance Regarding the FPMAJ's Pricing System Reform Proposal: Dr Takeshima
May 19, 2008
- Takeda: Heavy R&D Costs Cut Operating Profits
May 19, 2008
- Korosho to Consider Creating Japanese Version of FDA
May 19, 2008
- Pletaal Launched in Sweden: Otsuka
May 19, 2008
- Life Science Summit Calls For Creation of Japanese Version of FDA, NIH, OSCHR
May 19, 2008
- Bayer to Grow Twice as Fast as Market Aiming at \200 Bil. Sales: President J-L Lowinski
May 19, 2008
- Divergent Opinions on Japanese Version of FDA among LDP Members
May 19, 2008
- Daiichi Sankyo to Apply for Combination of Olmetec and Calblock
May 19, 2008
- Banyu's Isentress Roughly Recommended for Approval
May 19, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…